5G1: Phase I/II trial

Alexion Pharmaceuticals Inc. (ALXN), New Haven, Conn. Product: 5G1.1-SC, recombinant inhibitor of C5 in the complement cascade in inflammation Indication: Cardiopulmonary bypass surgery Status: ALXN ...